Symbols

IMCR

Immunocore·NASDAQ

--(--)

IMCR fundamentals

IMCR Q4 2025 Earnings

Immunocore (IMCR) released its earnings on Feb 25, 2026: revenue was 104.48M (YoY +24.30%), missed estimates; EPS was -0.6 (YoY -27.66%), missed estimates.

Revenue / YoY

104.48M

+24.30%

EPS / YoY

-0.6

-27.66%

Report date

Feb 25, 2026

IMCR Earnings Call Summary for Q4,2025

Revenue Surge: 29% YoY growth to $400M, fueled by U.S. community adoption and global expansion.
Clinical Milestones: 28-month OS in real-world data; TEBE-AM Phase III targeting 2026 readout for second-line melanoma.
Pipeline Momentum: HIV program shows delayed viral rebound; Type 1 diabetes Phase I trial begins H1 2026.
Financial Strength: $864M cash; 2026 growth expected to moderate to 4-7% QoQ.
Strategic Focus: Defending KIMMTRAK's leadership in melanoma with OS data, expanding into cutaneous melanoma.

Earnings

EPS

Revenue

Revenue & Expenses

IMCR has released its 2025 Q4 earnings report, with revenue of 104.48M, reflecting a YoY change of 24.30%, and net profit of -30.06M, showing a YoY change of -26.46%. The Sankey diagram below clearly presents IMCR's revenue sources and cost distribution.

Key Indicators

Immunocore (IMCR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Immunocore (IMCR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Immunocore (IMCR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Immunocore (IMCR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown